Carcinoid Tumor Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive
- Ankit Nigam
- Aug 6, 2020
- 5 min read

(Albany, NY) Delveinsight has launched a new report on "Carcinoid Tumor Market Insights, Epidemiology, and Market Forecast-2030”.
DelveInsight's "Carcinoid Tumor Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Carcinoid Tumor , historical and forecasted epidemiology as well as the Carcinoid Tumor market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
· Literature studies suggest that women are more likely to develop carcinoid tumors than men.
· The incidence of Neuroendocrine tumors was approximately 2/100,000 with a female preponderance under the age of 50 years due to appendiceal location. The main primary sites were the gastrointestinal tract (62–67%) and the lung (22–27%). Presentation with metastatic disease accounts for 12–22%.
· According to the American Society of Clinical Oncology (ASCO) in 2016, approximately 8,000 adults in the US were diagnosed with a carcinoid tumor in their GI tract.
· It is estimated that each year approximately 4,000 adults in the United States diagnose with the carcinoid tumor in their lung.
Request for Free Sample Report: https://www.delveinsight.com/sample-request/carcinoid-tumor-market
The Carcinoid Tumor report covers the descriptive overview of Carcinoid Tumor , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Carcinoid Tumor epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Carcinoid Tumor are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Carcinoid Tumor market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The Carcinoid Tumor report provides an edge while developing business strategies, by understanding trends shaping and driving the global Carcinoid Tumor market
Carcinoid Tumors are a type of slow-growing cancers that can arise in several places throughout the body and are characterized by the production of an excess of hormone-like substances, such as serotonin, bradykinin, histamine, and prostaglandins which leads to the other associated complications. These tumors, are the subset of neuroendocrine tumors and usually begin in the digestive tract (stomach, appendix, small intestine, colon, and rectum) or in the lungs. On the basis of their location of origin, these tumors are categorized into three areas as Foregut: The foregut includes the lungs and the stomach; Midgut: comprised of the small intestine, appendix, and the beginning of the large bowel (colon), and Hindgut: composed of the end of the large bowel, the rectum and the organs of the genitourinary tract (ovaries, testes).
Request for Free Sample Report: https://www.delveinsight.com/sample-request/carcinoid-tumor-market
In the terms of their reported occurrence, CT most commonly develops in the gastrointestinal tract. However, they can also occur in other parts of the body such as the lungs, ovaries, or testicles. Based on the location and size of the tumor, CT usually presents with the subset of the symptoms such as cutaneous flushing, itching, and palpitation, edema, salivation, upper body erythema, chronic diarrhea, malabsorption, and breathing difficulties, etc. Till now, the associated causes of CT remains largely unknown, however common risk factors includes getting affected with disorders, such as multiple endocrine neoplasia, pernicious anemia, or Zollinger- Ellison syndrome, etc.
· Amgen Inc.
· Novartis AG
· Exelixis, Inc.
· AVEO Pharmaceuticals, Inc.
· Boehringer Ingelheim GmbH
· Aegis Therapeutics, LLC
· Chiasma, Inc.
· Delcath Systems Inc.
· CRINETICS PHARMACEUTICALS
· And Many Others.
Request for Free Sample Report: https://www.delveinsight.com/sample-request/carcinoid-tumor-market
1. Key Insights
2. Executive Summary of Carcinoid Tumor
3. Competitive Intelligence Analysis for Carcinoid Tumor
4. Carcinoid Tumor : Market Overview at a Glance
4.1. Carcinoid Tumor Total Market Share (%) Distribution in 2017
4.2. Carcinoid Tumor Total Market Share (%) Distribution in 2030
5. Carcinoid Tumor : Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Carcinoid Tumor Pathophysiology
5.4. Carcinoid Tumor Risk Factors
5.5. Carcinoid Tumor Diagnosis
6. Patient Journey
7. Carcinoid Tumor Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Carcinoid Tumor Epidemiology Scenario: 7MM
7.3.1. Carcinoid Tumor Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Carcinoid Tumor Epidemiology
7.4.1. Carcinoid Tumor Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Carcinoid Tumor Epidemiology
7.5.1.1. Carcinoid Tumor Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Carcinoid Tumor Epidemiology
7.5.2.1. Carcinoid Tumor Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Carcinoid Tumor Epidemiology
7.5.3.1. Carcinoid Tumor Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Carcinoid Tumor Epidemiology
7.5.4.1. Carcinoid Tumor Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Carcinoid Tumor Epidemiology
7.5.5.1. Carcinoid Tumor Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Carcinoid Tumor Epidemiology
7.5.6.1. Carcinoid Tumor Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Carcinoid Tumor Treatment and Management
8.2. Carcinoid Tumor Treatment Algorithm
9. Carcinoid Tumor Unmet Needs
10. Key Endpoints of Carcinoid Tumor Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Carcinoid Tumor Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Carcinoid Tumor : Seven Major Market Analysis
13.1. Key Findings
13.2. Carcinoid Tumor Market Size in 7MM
13.3. Carcinoid Tumor Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Carcinoid Tumor Market Size
15.1.1. Carcinoid Tumor Total Market Size in the United States
15.1.2. Carcinoid Tumor Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Carcinoid Tumor Market Size
15.3.1. Carcinoid Tumor Total Market Size in Germany
15.3.2. Carcinoid Tumor Market Size by Therapies in Germany
15.4. France Carcinoid Tumor Market Size
15.4.1. Carcinoid Tumor Total Market Size in France
15.4.2. Carcinoid Tumor Market Size by Therapies in France
15.5. Italy Carcinoid Tumor Market Size
15.5.1. Carcinoid Tumor Total Market Size in Italy
15.5.2. Carcinoid Tumor Market Size by Therapies in Italy
15.6. Spain Carcinoid Tumor Market Size
15.6.1. Carcinoid Tumor Total Market Size in Spain
15.6.2. Carcinoid Tumor Market Size by Therapies in Spain
15.7. United Kingdom Carcinoid Tumor Market Size
15.7.1. Carcinoid Tumor Total Market Size in the United Kingdom
15.7.2. Carcinoid Tumor Market Size by Therapies in the United Kingdom
15.8. Japan Carcinoid Tumor Market Outlook
15.8.1. Japan Market Size
15.8.2. Carcinoid Tumor Total Market Size in Japan
15.8.3. Carcinoid Tumor Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Carcinoid Tumor
17. KOL Views
18. Carcinoid Tumor Market Drivers
19. Carcinoid Tumor Market Barriers
20. Appendix
20.1. Bibliography
20.2. Carcinoid Tumor Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Request for Detailed Toc: https://www.delveinsight.com/sample-request/carcinoid-tumor-market
About DelveInsight
DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for
Browse through our vast repository from here.
Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: info@delveinsight.com Phone: +19193216187 City: Albany State: New York Country: United States Website: https://www.delveinsight.com/


Comments